title: Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.
abstract: Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant gamma-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. gamma-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.
authors: University of Texas Health Science Center, San Antonio 78284-7884.
authors: D D
authors: DD
authors: Von Hoff
authors: T R
authors: TR
authors: Fleming
authors: J S
authors: JS
authors: Macdonald
authors: P J
authors: PJ
authors: Goodman
authors: J
authors: J
authors: Van Damme
authors: T D
authors: TD
authors: Brown
authors: T
authors: T
authors: O'Rourke
authors: L G
authors: LG
authors: Feun
authors: M D
authors: MD
authors: Keppen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D007371:Interferon-gamma